Risk stratification in Waldenström macroglobulinemia

Pierre Morel, Giampaolo Merlini

Research output: Contribution to journalArticlepeer-review


Waldenström macroglobulinemia is characterized by the production of serum monoclonal IgM and lymphoplasmacytic bone marrow infiltration. At least 25% of patients are asymptomatic at diagnosis and treatment is only mandatory in cases of symptomatic disease. Beside reports on treatment results, reviewing risk assessment is another way to describe the clinical course of the disease. This information may be particularly useful when numerous treatment options are available. While the introduction of new treatment approaches reinforces the need for careful risk assessment, the identification of useful prognostic information requires prolonged follow-up in patients who have not been treated with current therapeutic options. This limitation should be taken into account when using and interpreting available prognostic information, especially survival estimates.

Original languageEnglish
Pages (from-to)187-199
Number of pages13
JournalExpert Review of Hematology
Issue number2
Publication statusPublished - 2012


  • prognosis
  • risk assessment
  • therapy design
  • Waldenström macroglobulinemia

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Risk stratification in Waldenström macroglobulinemia'. Together they form a unique fingerprint.

Cite this